References
- Birmizngham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid for the treatment of multidrug-resistant, Gram-positive infections: experience from a compassionate-use programme. Clin Infect Dis 2003; 36: 159–68
- Mancino P, Ucciferri C, Falasca K, Pizzigallo E, Vecchiet J. Methicillin-resistant Staphylococcus epidermidis (MRSE) endocarditis treated with linezolid. Scand J Infect Dis 2008; 40: 67–73
- Patel R, Rouse MS, Piper KE, Steckelberg JM. Linezolid therapy of vancomycin-resistant Enterococcus faecium experimental endocarditis. Antimicrob Agents Chemother 2001; 45: 621–3
- Falagas ME, Manta KG, Ntziora F, Vardakas KZ. Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J Antimicrob Chemother 2006; 58: 273–80
- Olson CM, Rennie D, Cook D, Dickersin K, Flanagin A, Hogan JW, et al. Publication bias in editorial decision making. JAMA 2002; 287: 2825–8
- Olaison L, Schadewitz K. Enterococcal endocarditis in Sweden: can shorter therapy with aminoglycosides be used?. Clinical Infectious Diseases 2002; 34: 159–66